What Lifestyle Advice Applies During CML TKI Treatment?
At a Glance
People taking TKIs for Philadelphia-positive CML can usually exercise, travel, work, and eat a varied diet, but they should follow their drug’s food rules, avoid interactions, protect liver health, adjust activity to blood counts, and plan medication and testing when traveling.
In this answer
3 sections
Yes, you can generally exercise, travel, work, and enjoy a largely normal diet while taking a tyrosine kinase inhibitor (TKI) for Philadelphia-positive CML. However, because consistent daily medication helps maintain your treatment response, you will need to make some practical adjustments. These include protecting your liver, avoiding specific drug interactions, adjusting physical activity based on your blood counts, and ensuring you have a solid plan for managing your medication when traveling.
Diet, Alcohol, and Drug Interactions
While there is no single “CML diet,” what you eat, drink, and take over-the-counter can directly affect how your body absorbs and processes your medication.
- Food Instructions: The rules about food depend entirely on your specific TKI [1]. For example, some must be taken with food (such as imatinib or bosutinib) to improve absorption or reduce nausea. Others (such as nilotinib) must be taken strictly on an empty stomach to prevent excessive absorption that can lead to severe toxicity [2]. Always check your specific medication label and follow your pharmacist’s instructions exactly.
- Grapefruit and CYP3A4 Interactions: Most TKIs are metabolized (broken down) by a specific liver enzyme called CYP3A4 [3]. Grapefruit and Seville oranges can inhibit this enzyme, increasing the TKI in your blood to unsafe levels. Many herbal supplements (like St. John’s Wort) and prescription medicines also affect CYP3A4 [4]. Always consult your oncology pharmacist before starting any new supplement or medication [5].
- Antacids and Acid Reducers: This is a separate interaction from CYP3A4. Some TKIs require stomach acid to be properly absorbed. Taking antacids or acid-reducing medications (like proton pump inhibitors or H2 blockers) can prevent the TKI from entering your system. The exact restrictions vary significantly by drug, so consult your care team before taking heartburn medication [4].
- Alcohol Considerations: Hepatotoxicity (liver injury or inflammation, identified by elevated AST and ALT liver enzymes on blood tests) is a risk with several CML TKIs, particularly bosutinib, nilotinib, and ponatinib [6] [7]. Because your liver processes your medication, discuss your alcohol consumption with your doctor. People with abnormal liver tests or underlying liver disease may be advised to avoid alcohol entirely.
Exercise and Managing Symptoms
Staying active is highly beneficial for your health and can improve treatment-related fatigue over time [8] [9]. However, your routine should be individualized based on your symptoms and blood counts [10] [11].
- Listening to Your Blood Counts: TKIs can cause myelosuppression (a drop in healthy blood cell counts) [12]. If you develop anemia (low red blood cells), you may experience significant fatigue and shortness of breath [13] [14]. Low platelets (thrombocytopenia) can increase your risk of bleeding or bruising, making contact sports dangerous, while low white blood cells (neutropenia) increase your risk of infection [12]. Wait until your care team confirms your counts are stable before starting a strenuous new fitness routine.
- Professional Guidance: If you struggle with severe fatigue or have cardiovascular conditions, ask for a referral to an accredited exercise physiologist or physical therapist experienced in cancer care to help you design a safe, tailored program [15].
When to Seek Urgent Care
Do not try to exercise through severe symptoms. Contact your care team or seek urgent medical attention if you experience:
- New or severe shortness of breath
- Chest pain, rapid heartbeat, or fainting
- Unusual bleeding or excessive bruising
- Jaundice (yellowing of the skin or eyes) or dark urine
- Severe, persistent diarrhea or vomiting
Travel Guidelines and Medication Management
Traveling is highly achievable with CML, but it requires careful preparation. Taking your daily TKI consistently helps maintain a deep molecular response [12] [4].
- Medication Supply and Storage: Bring extra medication (more than the trip requires) and always carry your TKIs in your carry-on luggage to avoid lost bags. Keep your medication in its original packaging—many oral anticancer drugs are sensitive to moisture and degrade if placed in standard pill organizers [16] [17]. Consider using a daily phone alarm instead of a pillbox.
- Time-Zone Adjustments: Maintaining the correct interval between doses is important to keep steady drug levels and manage food interactions [2]. If you are crossing multiple time zones, ask your care team for a plan to safely shift your dose timing.
- Missed or Vomited Doses: If you miss a dose or vomit shortly after taking your TKI, do not double your next dose unless specifically instructed to do so by your care team or the product label.
- Routine Testing on the Road: CML care involves regular monitoring, including complete blood counts (CBC), liver function tests, and a quantitative PCR (qPCR) blood test. This PCR test measures your BCR::ABL1 transcript levels (the genetic marker for CML) to ensure the drug is working [18]. This is typically done every 3 months initially, and continues long-term [19]. Results are reported on an International Scale (IS) to keep them standardized [20]. If you are traveling long-term, do not postpone a required test; work with your care team to arrange testing at a local, appropriately standardized laboratory [21].
Common questions in this guide
Can I exercise while taking a TKI for CML?
What foods, drinks, or medicines should I avoid with my CML TKI?
Is alcohol safe during Philadelphia-positive CML treatment?
Can I travel while taking daily CML medication?
What should I do if I miss or vomit a CML TKI dose?
How can I keep up with CML monitoring during a long trip?
When should I seek urgent help during CML treatment?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Travel and medication
Should I bring extra medication and carry my TKI in my carry-on when I travel?
Alcohol and the liver
Should I ask my doctor how much alcohol is safe while I take my TKI?
Food and interactions
Should I ask my oncology pharmacist about grapefruit and antacids with my TKI?
Related questions
Show more
Get notified when new evidence is published on Philadelphia-positive myelogenous leukemia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (21)
- 1
BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Cuellar S, Vozniak M, Rhodes J, et al.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2018; (24(6)):433-452 doi:10.1177/1078155217710553.
PMID: 28580869 - 2
Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative study.
Tan BK, Tan SB, Chen LC, et al.
Patient preference and adherence 2017; (11()):1027-1034 doi:10.2147/PPA.S132894.
PMID: 28652712 - 3
Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
Hsyu PH, Pignataro DS, Matschke K
European journal of clinical pharmacology 2017; (73(1)):49-56 doi:10.1007/s00228-016-2108-z.
PMID: 27718000 - 4
Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors.
Kondapalli L, Worth S, Hawi R, et al.
Vascular medicine (London, England) 2020; (25(3)):246-254 doi:10.1177/1358863X20906868.
PMID: 32303152 - 5
Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
Lam MS, Cheung N
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2016; (22(6)):741-748 doi:10.1177/1078155215608523.
PMID: 26419691 - 6
Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Wang Z, Wang X, Wang Z, et al.
JAMA network open 2021; (4(7)):e2120165 doi:10.1001/jamanetworkopen.2021.20165.
PMID: 34292334 - 7
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Cortes JE, Gambacorti-Passerini C, Deininger MW, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(3)):231-237 doi:10.1200/JCO.2017.74.7162.
PMID: 29091516 - 8
Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline.
Ligibel JA, Bohlke K, May AM, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(22)):2491-2507 doi:10.1200/JCO.22.00687.
PMID: 35576506 - 9
A Current Overview of Quality-of-Life Research in Chronic Myeloid Leukemia (CML).
Deneberg S
Cancers 2026; (18(7)) doi:10.3390/cancers18071133.
PMID: 41976356 - 10
Exercise for people with cancer: a systematic review.
Segal R, Zwaal C, Green E, et al.
Current oncology (Toronto, Ont.) 2017; (24(4)):e290-e315 doi:10.3747/co.24.3619.
PMID: 28874900 - 11
The Exercise and Sports Science Australia position statement: Exercise medicine in cancer management.
Hayes SC, Newton RU, Spence RR, Galvão DA
Journal of science and medicine in sport 2019; (22(11)):1175-1199 doi:10.1016/j.jsams.2019.05.003.
PMID: 31277921 - 12
Chronic Myeloid Leukemia: A Review.
Jabbour E, Kantarjian H
JAMA 2025; (333(18)):1618-1629 doi:10.1001/jama.2025.0220.
PMID: 40094679 - 13
Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase.
Moura MS, Benevides TCL, Delamain MT, et al.
Hematology, transfusion and cell therapy 2019; (41(4)):329-334 doi:10.1016/j.htct.2019.03.006.
PMID: 31395459 - 14
Prevalence of Anemia among Chronic Myeloid Leukemia Patients Treated with Imatinib: A Evidence-based Meta-analysis.
Singh AK, Kumar A, Agrawal N, et al.
Current reviews in clinical and experimental pharmacology 2023; (18(2)):148-157 doi:10.2174/2772432817666220315144253.
PMID: 35293301 - 15
Clinical Oncology Society of Australia position statement on exercise in cancer care.
Cormie P, Atkinson M, Bucci L, et al.
The Medical journal of Australia 2018; (209(4)):184-187 doi:10.5694/mja18.00199.
PMID: 29719196 - 16
Actual versus recommended storage temperatures of oral anticancer medicines at patients' homes.
Vlieland ND, van den Bemt B, van Riet-Nales DA, et al.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2019; (25(2)):382-389 doi:10.1177/1078155217741767.
PMID: 29187027 - 17
Challenges of dispensing costly tablets with short shelf-life.
de Lemos ML, Mathers B, Badry N, et al.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2019; (25(1)):210-213 doi:10.1177/1078155218777815.
PMID: 29768959 - 18
Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?
Branford S
Haematologica 2020; (105(12)):2730-2737 doi:10.3324/haematol.2019.240739.
PMID: 33054104 - 19
Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry).
Möbius S, Schenk T, Himsel D, et al.
Journal of cancer research and clinical oncology 2019; (145(6)):1645-1650 doi:10.1007/s00432-019-02910-6.
PMID: 30941573 - 20
[Guidelines for molecular monitoring of BCR-ABL1 in chronic myeloid leukemia patients by RT-qPCR].
Larripa I, Ruiz MS, Gutiérrez M, Bianchini M
Medicina 2017; (77(1)):61-72.
PMID: 28140313 - 21
Variant-specific BCR::ABL1 quantification discrepancy in chronic myeloid leukemia.
Jacobs K, Moerman A, Vandepoele K, et al.
International journal of laboratory hematology 2024; (46(5)):910-917 doi:10.1111/ijlh.14320.
PMID: 38840510
This page provides general information about lifestyle and medication safety during CML treatment and does not replace medical advice. Ask your CML care team or oncology pharmacist for personalized guidance about your TKI, blood counts, alcohol, exercise, and travel.